VJHemOnc is committed to improving our service to you

SOHO 2020 | Targeting p53 in MDS

VJHemOnc is committed to improving our service to you

David Sallman

David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses p53 mutations in the context of patients with myelodysplastic syndromes (MDS) and it’s association with survival. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter